Navigation Links
CSL Behring Study in Animal Models Shows Feasibility of Developing a Half-Life Extended Recombinant FVIIa that Retains Biologic Activity
Date:12/10/2007

In data presented at the ASH 49th annual meeting recombinant factor VIIa-albumin fusion protein seen as first step toward more convenient

treatment option for hemophilia patients with inhibitors

ATLANTA, Dec. 10 /PRNewswire/ -- CSL Behring today announced the results of a pre-clinical study that show for the first time it is feasible to genetically fuse Factor VIIa (FVIIa) to human albumin, prolonging the half- life of this therapeutic protein while retaining its biologic activity. In the study, which was presented at the American Society of Hematology 49th Annual Meeting and Exposition, the half-life of recombinant VIIa-albumin fusion protein (rVIIa-FP) was shown to be extended 6-to-9 fold compared to wild type rFVIIa. Additionally, rVIIa-FP demonstrated a biologic activity comparable to wild type rFVIIa.

Recombinant factor VIIa (rFVIIa) may be used to control bleeding episodes in hemophilia patients with inhibitors. These patients develop an immune response that inhibits the substituted clotting factor from stopping a bleeding episode. However, rFVIIa has a short half-life of approximately 2.5 hours. This necessitates multiple injections, which are inconvenient for both physicians and patients, particularly during surgical intervention.

"A major unmet need in hematology is improving the pharmacokinetic parameters of coagulation factors, such as half-life, while retaining full hemostatic activity," said Dr. Stefan Schulte, Head Pre-clinical R&D, CSL Behring GmbH and lead investigator of the study. "The pharmacological properties of rVIIa-FP seen in our study could one day facilitate a single dosing regimen of one injection per bleeding event, as well as significantly reduce the number of injections hemophilia patients with inhibitors need during surgical interventions."

Recombinant VIIa-FP represents CSL Behring's initial corporate foray into research with recombinant coagulation product technology.

"CSL Behring is pleased to be at the forefront of this exciting development in hemophilia treatment, which is consistent with our mission to improve the lives of patients with bleeding disorders," said Dr. Andrew Cuthbertson, Chief Scientific Officer at CSL Ltd., parent company of CSL Behring. "By increasing convenience and compliance, rVIIa-FP has the potential to benefit hemophilia patients with inhibitors and the physicians who treat those patients. We look forward to continuing our research and accumulating additional data to validate the results seen in our pre-clinical study of this molecule."

Today's Presentation: Study Design

Genetic fusion to albumin is an efficient way to extend the half-life of small proteins, but so far it has not been successfully used for the half-life extension of complex proteins. In the presented proof-of-principle study, rVIIa-FP was generated by genetic engineering, expressed in mammalian cell culture, purified and characterized. The rVIIa-FP displayed full biological activity and 6 to 9-fold extended half-life compared to either Novoseven(R)(1), a recombinant FVIIa, or rVIIa control protein in a pre-clinical rat model. The superior pharmacological properties of the rVIIa-FP could facilitate a single dosing regimen of one injection per bleeding event for treatment of hemophilia inhibitor patients.

About Hemophilia with Inhibitors

In some patients with hemophilia, the immune system produces an antibody that blocks the action of the substituted coagulation factor and prevents clot formation. This antibody is known as an inhibitor, and its presence makes treatment of bleeding episodes more difficult. The reason inhibitors develop is unknown, although people with hemophilia have the greatest risk for developing an inhibitor during childhood. The incidence of inhibitors is highest among those with severe hemophilia, followed by moderate and mild deficiency. The risk of inhibitor development is higher if someone in the patient's family also has an inhibitor, and is more frequent among African Americans.(2)

About CSL Behring

CSL Behring is a global leader in the protein biotherapeutics industry. Passionate about saving and improving the quality of patients' lives, CSL Behring manufactures and markets a range of safe and effective plasma-derived and recombinant products and related services. The company's therapies are used in the treatment of rare diseases such as immune deficiency disorders, hemophilia, von Willebrand disease, other bleeding disorders and inherited emphysema. Other products are used for the prevention of hemolytic diseases in the newborn, in cardiac surgery, organ transplantation and in the treatment of burns. The company also operates one of the world's largest plasma collection networks, ZLB Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company with headquarters in Melbourne, Australia. For more information, visit http://www.cslbehring.com.

Contacts: Sheila A. Burke Jeff Hoyak

Director, Communications & Public Relations MCS Public Relations

Worldwide Commercial Operations, CSL Behring +1-908-884-6753

+1-610-878-4209 jeffh@mcspr.com

Sheila.Burke@cslbehring.com

(1) NovoSeven is a registered trademark of Novo Nordisk Health Care AG.

(2) National Hemophilia Foundation website http://www.hemophilia.org

accessed 11.9.07


'/>"/>
SOURCE CSL Behring
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
8. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
9. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
10. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
11. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 The key factors ... increasing diabetic population, accelerating economic growth and increasing healthcare expenditure. ... are higher life expectancy of ESRD patients, rising demand for ... However, the expansion of the market is hindered by high ... ...
(Date:3/23/2017)... BARBARA, Calif. and INDIANAPOLIS ... (NYSE: LLY ) and the William Sansum ... the lives of Latino people affected by diabetes through ... tremendous burden of diabetes and cardiovascular disease bears a ... United States ," said David Kerr , ...
(Date:3/23/2017)... 2017   BioSpace , the leading biotechnology and ... Indiana Biosciences Research Institute and over 20 ... institutions to bring the state,s life sciences industry to ... an artistic representation of the region,s booming biotechnology and ... President Mike Pence , a long-time advocate of ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan ... to announce Westchester resident Lauren C. Enea has joined the firm as an associate ... concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts and ...
(Date:3/24/2017)... ... , ... “Finding Christ Through Social Media: Year One #A365DayJourney ... writer’s path toward true communion with God. “Finding Christ Through Social Media: Year ... of published author Lea Michelle Johnson, a follower of Christ, wife and mother ...
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health Organization declared ... be four million Zika-related cases in the Americas within the next year. Lyme disease ... reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect ...
(Date:3/23/2017)... ... 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on April ... will be an educational and exciting program providing busy clinicians and allied healthcare ... pain. , Oklahoma is in a healthcare crisis. The state ranks 46th in ...
(Date:3/23/2017)... ... 23, 2017 , ... March is National Kidney Month – the perfect time ... to maintaining good health. Every day, two kidneys filter about 120 to 150 quarts ... your blood, eliminating waste, regulating fluid levels and blood pressure, supporting bone health and ...
Breaking Medicine News(10 mins):